Wikidata

(Q47652109)

English

Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial

scientific article published on 15 January 2018

In more languages

Statements

title
Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
29353025
retrieved
4 February 2018
reference URL
http://europepmc.org/abstract/MED/29353025
author
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q47652109&oldid=2164174761"